Bain Capital to Offload 2.4% Stake in Emcure Pharmaceuticals for ₹551 Crore
BC Investments IV, backed by Bain Capital, plans to sell 2.4% (45.5 lakh shares) of Emcure Pharmaceuticals for ₹551 crore. The offer price is ₹1,225 per share, a 4% discount to the current market price. The block deal, to be executed through Kotak Securities, comes after Emcure reported strong Q4 results with a 63% increase in profit after tax to ₹197 crore and a 19.5% rise in revenue to ₹2,116 crore.

*this image is generated using AI for illustrative purposes only.
Emcure Pharmaceuticals is set to see a change in its shareholding as Bain Capital-backed BC Investments IV plans to reduce its stake through a significant block deal, according to recent market reports. The private equity firm intends to sell approximately 2.4% of its holdings in the pharmaceutical company, aiming to raise ₹551 crore.
Block Deal Details
Aspect | Detail |
---|---|
Stake for Sale | 2.4% (45.5 lakh shares) |
Total Offer Size | ₹551.00 crore |
Floor Price | ₹1,279.80 per share |
Offer Price | ₹1,225.00 per share |
Discount | 4% to the current market price |
Execution Date | Friday (upcoming) |
Book Runner | Kotak Securities |
The offer price of ₹1,225.00 per share represents a 4% discount to Emcure Pharmaceuticals' current market price, potentially making it an attractive proposition for institutional investors looking to acquire a substantial stake in the company.
Recent Financial Performance
Emcure Pharmaceuticals has recently reported strong financial results for the fourth quarter:
Metric | Result |
---|---|
Q4 Profit After Tax (PAT) | ₹197.00 crore, up 63% year-over-year |
Q4 Revenue | ₹2,116.00 crore, an increase of 19.5% year-over-year |
The company's robust financial performance may contribute to investor interest in the upcoming block deal.
Market Impact
This block deal represents a significant movement of shares and could potentially impact Emcure Pharmaceuticals' stock price in the short term. Investors and market analysts will be closely watching the execution of this transaction and its effect on the company's shareholding pattern.
The successful completion of this block deal would mark a partial exit for Bain Capital from its investment in Emcure Pharmaceuticals, potentially signaling a shift in the company's ownership structure.
As the pharmaceutical sector continues to be a focus of investor interest, particularly in the wake of global health challenges, this transaction may also reflect broader trends in private equity strategies within the healthcare and life sciences industries.
Historical Stock Returns for Emcure Pharmaceuticals
1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|
+0.72% | -2.93% | -3.23% | -12.64% | -5.84% | -5.84% |